Evidence map›Paper›PMID 38818368›Full record

ArticleLung cancer management2024

Inflammatory parameters in NSCLC with driver mutation.

Mehmet Emin Buyukbayram, Zekeriya Hannarici, Ali Yilmaz, Aykut Turhan, Alperen Akansel Caglar, Pınar Coban Esdur, Mehmet Bilici, Salim Basol Tekin

Abstract read
In one paragraph

Article in Lung cancer management, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mehmet Emin BuyukbayramDepartment of Medical Oncology, Atatürk University Faculty of Medicine, Erzurum, 25100, Turkey.ORCID https://orcid.org/0000-0002-5454-7576
Zekeriya HannariciDepartment of Medical Oncology, Nev Hospital, Sanliurfa, 63000, Turkey.ORCID https://orcid.org/0000-0002-6547-0199
Ali YilmazDepartment of medical Oncology, Health Sciences University Yüksek İhtisas Training and Research Hospital, Bursa, 16350, Turkey.ORCID https://orcid.org/0000-0001-6078-8651
Aykut TurhanDepartment of Medical Oncology, Atatürk University Faculty of Medicine, Erzurum, 25100, Turkey.ORCID https://orcid.org/0000-0002-2535-9816
Alperen Akansel CaglarDepartment of Medical Oncology, Atatürk University Faculty of Medicine, Erzurum, 25100, Turkey.ORCID https://orcid.org/0000-0001-8541-3418
Pınar Coban EsdurDepartment of Medical Oncology, Atatürk University Faculty of Medicine, Erzurum, 25100, Turkey.ORCID https://orcid.org/0000-0002-4487-9139
Mehmet BiliciDepartment of Medical Oncology, Atatürk University Faculty of Medicine, Erzurum, 25100, Turkey.ORCID https://orcid.org/0000-0003-1306-2238
Salim Basol TekinDepartment of Medical Oncology, Atatürk University Faculty of Medicine, Erzurum, 25100, Turkey.ORCID https://orcid.org/0000-0002-0974-3412

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

driver mutationinflammatory markersnon-small-cell lung cancersurvival

Identifiers

PMID38818368
PMCPMC11137794

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.